Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-199P is a processed pseudogene of the U6 small nuclear RNA. U6 snRNA is a highly conserved noncoding RNA essential for spliceosome function, catalyzing pre-mRNA splicing in the nucleus[1][3]. However, RNU6-199P itself is a transcriptionally inactive genomic copy, typically formed by retrotransposition—specifically LINE-1 elements copying U6 snRNA into new locations in the genome[2]. These pseudogenes generally do not encode functional RNA or protein and serve as markers of retrotransposition history rather than having a biological or therapeutic role. Their presence may help researchers study genome evolution and retrotransposon activity but does not imply function in gene regulation, disease, or as a drug target[2][3]. If you are seeking data on the functional U6 small nuclear RNA, refer to "U6 small nuclear RNA" or "U6 snRNA" instead of this pseudogene designation[1][3]. If you need actual drug targets, the U6 pseudogene family is not included.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 199, pseudogene (RNU6-199P).